Sleep physicians, hospitals and sleep laboratories, home healthcare providers and durable medical equipment suppliers are the buyers in the sleep apnea devices market. They purchase diagnostic instruments such as polysomnography systems, respiratory polygraphs, pulse oximeters and actigraphs, along with positive airway pressure systems, masks and oral interface accessories, then prescribe, dispense and service that equipment for patients on ongoing therapy.
Contrive Datum Insights sizes the market at USD 8.5 billion in 2025. The study projects USD 9.16 billion in 2026 and USD 17.35 billion by 2034, a compound annual growth rate of 8.31% across the forecast period. The release covers product type, end user, oral devices, indication and distribution channel, with figures for every line from 2020 to 2034.
Where Buyer Spending Is Concentrating
By product type, CPAP carries the most revenue, at 42% of 2025 sales and USD 3.57 billion. It slips to 38% of the market by 2034 and grows at 7.09%, slower than the market as a whole. Respiratory Polygraphs is the fastest-growing line at 13.23%, lifting its share from 8% to 12% and its value from USD 0.68 billion to USD 2.08 billion. Rising diagnosed prevalence of obstructive sleep apnea is the largest single contributor to growth, and the study rates its impact high.
The buyer mix tells a similar story. Sleep Physicians account for 48% of 2025 revenue at USD 4.08 billion, while Homecare Nurses grow fastest among end users at 9.77%. Among oral devices, Sleep Apnea Masks lead with 58% of revenue at USD 4.93 billion, and Nasal Devices expand fastest at 9.87%.
Obstructive Sleep Apnea (OSA) is the dominant indication at 86.94% of revenue, or USD 7.39 billion, yet Complex/Mixed Sleep Apnea grows fastest at 12.09%. On the purchasing side, Durable Medical Equipment (DME) Suppliers handle 62% of revenue at USD 5.27 billion, and Online Channels are the quickest to grow at 13.93%.
North America is the largest region, holding 41% of global revenue in 2025 at USD 3.49 billion and reaching USD 6.59 billion by 2034. The United States is the largest single country market at USD 2.97 billion, or 34.94% of global revenue. Asia Pacific gains ground, moving from 21% of revenue in 2025 to 26% in 2034, with revenue rising from USD 1.79 billion to USD 4.51 billion. Middle East and Africa remains the smallest region, at 5.8% of 2025 revenue and 5.5% by 2034.
The growth outlook depends on how quickly diagnosis turns into treatment. In the study's bull case, faster payer coverage expansion and an accelerated home sleep testing rollout across mid-sized health systems push 2034 revenue to USD 19.43 billion. In the bear case, slower reimbursement expansion and persistent PAP therapy nonadherence hold it to USD 15.27 billion. The base case of USD 17.35 billion sits between the two.
The report is delivered as a PDF and includes the competitive landscape, country-level breakdowns for all five regions, and the research methodology behind every estimate. A free sample is available on request.